Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt small index

Food Allergy: early-phase trial registry

9 of 18 indexed Food Allergy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #953 of 28,707 conditions by registered trial count.

18 US clinical trials · 9 currently recruiting · #953 of 28,707 conditions by registered trial count

Food Allergy: 18 US clinical trials tracked, 9 recruiting.

Food Allergy is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 2 of these trials.

Enrollment posture brief

Registry condition food-allergy

OPEN 9 | RECR 50% | LATE 2 | EARLY 10 | RANK #953 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Food Allergy (this)50%Arrhythmias, Cardiac27.8%Androgenetic Alopecia16.7%Anemia, Sickle Cell16.7%Acquired Immunodeficiency Sy5.6%
Open-enrollment share among volume-matched conditions near Food Allergy

Food Allergy lists 9 open slots (50% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Food Allergy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Food Allergy is recruiting above its size-band peers.

    9 of 18 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Food Allergy trials is spread across many organizations.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 2 of 18 trials (11.1%). 17 distinct sponsors appear on at least one study for this condition label.

  3. Most Food Allergy trials plan to enrol fewer than 100 people.

    Median target enrolment is 73 among the 18 trials that report a genuine target (sentinel values excluded). 12 of those (66.7%) plan for fewer than 100 participants.

  4. Food Allergy research is mostly interventional.

    13 interventional and 5 observational studies make up this index (72.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 26Phase 42

Open and recent trials

18 total, page 1 of 1

RECRUITING 5,000 participants

Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders

Children's Hospital Medical Center, Cincinnati

NCT00267501

RECRUITING 1,800 participants

Natural History and Genetics of Food Allergy and Related Conditions

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02504853

RECRUITING 1,000 participants

Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

Stanford University

NCT03539692

RECRUITING NA 200 participants

Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project

University of Michigan

NCT06300697

RECRUITING Phase 4 40 participants

Effect of Omalizumab in the Skin of Food Allergy Patients

National Jewish Health

NCT06618963

RECRUITING Phase 2 37 participants

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

Rima Rachid

NCT05695261

RECRUITING Phase 1 30 participants

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

Insignis Therapeutics

NCT07210320

RECRUITING Phase 2 30 participants

Omalizumab Weight-Based Dosing Efficacy Trial

Massachusetts General Hospital

NCT06943534

RECRUITING Phase 1 6 participants

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Regeneron Pharmaceuticals

NCT06369467

ACTIVE NOT RECRUITING 2,500 participants

Systems Biology of Early Atopy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04798079

ACTIVE NOT RECRUITING Phase 4 20 participants

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

AAADRS Clinical Research Center

NCT06437171

COMPLETED 5,374 participants

Effects of Infant Egg Consumption on Child Health and Cognition Development

State University of New York at Buffalo

NCT04345185

COMPLETED Phase 2 92 participants

Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy

Hugh A Sampson, MD

NCT01846208

COMPLETED Phase 2 73 participants

Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy

Scott Sicherer

NCT03907397

COMPLETED Phase 1 73 participants

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

Alladapt Immunotherapeutics

NCT04856865

COMPLETED Phase 2 70 participants

Multi Immunotherapy to Test Tolerance and Xolair

Kari Christine Nadeau

NCT02626611

COMPLETED Phase 1 36 participants

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

Boston Children's Hospital

NCT01781637

COMPLETED Phase 2 10 participants

Preventing Anaphylaxis With Acalabrutinib

Johns Hopkins University

NCT05038904

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 6
Phase 4 2

Named interventions

Most-linked intervention names on Food Allergy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Omalizumab Drug
2 trials
Infant egg consumption (i.e., age of introduction and frequency of intake) Other
1 trials
Food Flour Buildup Drug
1 trials
Pooled Placebo Biological
1 trials
High dose ADP101 Biological
1 trials
Low dose ADP101 Biological
1 trials
Baked Egg Drug
1 trials
Egg Oral Immunotherapy Drug
1 trials

US sites by state

Facility locations filed on Food Allergy trials. A trial with sites in several states counts in each.

New York 6 trials
Massachusetts 5 trials
California 5 trials
Pennsylvania 4 trials
Ohio 4 trials
North Carolina 4 trials
Maryland 4 trials
Illinois 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Food Allergy page

18 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Food Allergy condition card totals 18 registered trials; most-linked intervention Omalizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.